PMID- 27203172 OWN - NLM STAT- MEDLINE DCOM- 20170307 LR - 20170307 IS - 0040-5957 (Print) IS - 0040-5957 (Linking) VI - 71 IP - 5 DP - 2016 Oct TI - [Use of psychostimulants in a sexual context: Analysis of cases reported to the French network of Addictovigilance Centers]. PG - 447-455 LID - S0040-5957(16)30012-9 [pii] LID - 10.1016/j.therap.2016.04.003 [doi] AB - The "SLAM" phenomenon is an increasingly popular practice, in Paris and London gay scene, defined by 3 characteristics: injection, sexual party and psychostimulant drugs. The French Medical Agency requested a risk assessment of "SLAM" and more broadly of the use of psychostimulants in a sexual context, by the analysis of complications related to this practice notified to the French Network of Addictovigilance Centers. All cases of complications related to "SLAM" practice, including cases of abuse or dependence, and somatic and psychiatric complications, were analysed. Between January 2008 to December 2013, 51 cases were collected. Users were exclusively men, with a mean age of 40 years, having psychostimulants exposure in a sexual context, mainly in men who have sex with men (MSM) context (100%, n=35). The prevalence of human immunodeficiency virus (HIV) infection was 82% (n=32) with a high level of HIV/hepatitis C virus (HCV) co-infection (50%, n=16). The main psychostimulants reported are synthetic cathinones (89.5%). Cathinones users tended to be polydrug users: 62% also reported use other than psychoactive substances (gamma-butyrolactone [GBL], ketamine, methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD]...). The main complications were psychiatric disorders in 50% (psychotic symptoms, agitation, anxiety, suicidal ideas or attempt and forensic problems), acute intoxication in 25% (including 3 deaths), dependence and abuse in 17% and infectious complications in 8% (viral seroconversion). Health professionals as well as users should be aware of the physical (cardiovascular) and behavioural (psychic, fast dependence syndrome) toxicity of cathinones. Risk reduction policy must be targeted to the population of MSM with specific interventions both on risky sexual behavior and substance use. CI - Copyright (c) 2016 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved. FAU - Batisse, Anne AU - Batisse A AD - Centre d'addictovigilance d'Ile-de-France, Centre GHU Lariboisiere-Fernand-Widal, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France. Electronic address: anne.batisse@aphp.fr. FAU - Peyriere, Helene AU - Peyriere H AD - Centre d'addictovigilance, hopital Lapeyronie, 34295 Montpellier, France; UMI 233/Inserm U1175, 34294 Montpellier, France. FAU - Eiden, Celine AU - Eiden C AD - Centre d'addictovigilance, hopital Lapeyronie, 34295 Montpellier, France. FAU - Courne, Marie-Anne AU - Courne MA AD - Agence nationale de securite du medicament et des produits de sante, 93285 Saint-Denis, France. FAU - Djezzar, Samira AU - Djezzar S AD - Centre d'addictovigilance d'Ile-de-France, Centre GHU Lariboisiere-Fernand-Widal, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France. CN - Reseau francais des centres d'addictovigilance LA - fre PT - Journal Article TT - Usage de psychostimulants dans un contexte sexuel : analyse des cas rapportes au Reseau francais des centres d'addictovigilance. Evaluation des risques lies a la pratique du SLAM. DEP - 20160426 PL - France TA - Therapie JT - Therapie JID - 0420544 RN - 0 (Psychotropic Drugs) SB - IM MH - Adult MH - France/epidemiology MH - HIV Infections/epidemiology MH - *Homosexuality, Male MH - Humans MH - Male MH - Middle Aged MH - Psychotropic Drugs/*adverse effects MH - *Risk-Taking MH - Substance-Related Disorders/*epidemiology MH - Young Adult OTO - NOTNLM OT - Cathinones de synthese OT - Homme homosexuel OT - Male homosexuality OT - Sexuality OT - Sexualite OT - Substance-related disorders OT - Synthetic cathinones OT - Troubles lies a l'usage de substances EDAT- 2016/05/21 06:00 MHDA- 2017/03/08 06:00 CRDT- 2016/05/21 06:00 PHST- 2015/11/19 00:00 [received] PHST- 2016/04/01 00:00 [accepted] PHST- 2016/05/21 06:00 [pubmed] PHST- 2017/03/08 06:00 [medline] PHST- 2016/05/21 06:00 [entrez] AID - S0040-5957(16)30012-9 [pii] AID - 10.1016/j.therap.2016.04.003 [doi] PST - ppublish SO - Therapie. 2016 Oct;71(5):447-455. doi: 10.1016/j.therap.2016.04.003. Epub 2016 Apr 26.